IDO1 and glioblastoma: Current investigations are evaluating IDO1 inhibition in specific tumor types with high immunosuppressive microenvironments (e.g., glioblastoma, ovarian cancer) and in earlier disease settings, such as neoadjuvant and adjuvant therapy, where immune modulation may be more effective.